Trial Profile
Long-term Follow-up and/or Continued Thalidomide (THALOMID®) Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Thalidomide (Primary)
- Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 30 Aug 2023 Status changed from active, no longer recruiting to completed.
- 09 Sep 2021 Planned End Date changed from 1 Nov 2021 to 1 Nov 2023.
- 09 Sep 2021 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2023.